Enoxaparin: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[DVT]] ''prophylaxis'' | ===Therapeutic anticoagulation=== | ||
''Treating [[DVT]]/[[PE]], [[unstable angina]]'' | |||
*1mg/kg SC q12h | |||
{{Chemical prophylaxis of VTE}} | |||
===[[DVT]] ''prophylaxis''=== | |||
*40mg SC daily | |||
30mg SubQ q12 hrs (if Cr Clearance > 30) | |||
==Pediatric Dosing== | ==Pediatric Dosing== |
Revision as of 17:56, 28 November 2019
General
- Type: Low molecular weight heparin
- Dosage Forms: subcutaneous
- Common Trade Names: Lovenox
Adult Dosing
Therapeutic anticoagulation
Treating DVT/PE, unstable angina
- 1mg/kg SC q12h
Chemical Prophylaxis of VTE
- Lovenox 30mg SubQ q12 hrs (if Cr Clearance > 30)
- Check Anti-Xa level every week EXACTLY 4 hours after 3rd dose of lovenox
- prophylactic goal: 0.2-0.6
- therapeutic goal: 0.6-1.2
- Check Anti-Xa level every week EXACTLY 4 hours after 3rd dose of lovenox
- Recheck AntiXa level after each 3rd dose if dose is changed until you are at goal
- Recheck level every week (usually qMonday) for all patients
- If renal dysfunction order heparin 5000 Units SubQ q8 hrs (search “SURG DVT/VTE prophylaxis” order set)
DVT prophylaxis
- 40mg SC daily
30mg SubQ q12 hrs (if Cr Clearance > 30)
Pediatric Dosing
Off-label
- DVT prophylaxis:
- <2 months: 0.75 mg/kg SC q12hr
- ≥2 months: 0.5 mg/kg SC q12h
- Therapeutic anticoagulation:
- <2 months: 1.5 mg/kg SC q12hr
- ≥2 months: 1 mg/kg SC q12hr
Special Populations
- Pregnancy Rating: B
- Lactation: Unknown risk
- Renal Dosing
- Renal impairment (creatinine clearance <30)
- Use 50% of usual dose or use UFH instead
- Renal impairment (creatinine clearance <30)
- Hepatic Dosing: not established
- Obesity
- Weight-based dosing safe up to 190kg (no data available thereafter)
Indications
Contraindications
- Allergy to class/drug
Adverse Reactions
- Bleeding
- Pruritus
- Local skin reaction
Pharmacology
- Half-life: 4.5h
- Metabolism: hepatic
- Excretion: urine
- Mechanism of Action: inhibits factor Xa by increasing inhibition rate of clotting proteases that are activated by antithrombin III